The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving erythropoiesis‐stimulating agents
Abstract
Background
Erythropoiesis‐stimulating agents (ESAs) are commonly used to treat chemotherapy‐induced anemia (CIA). However, about half of patients do not benefit.
Objectives
To evaluate the benefits and harms related to the use of iron as a supplement to ESA and iron alone compared with ESA alone in the management of CIA.
Search methods
We searched for relevant trials from the Cochrane Central Register of Controlled Trials (CENTRAL) (issue 1 January 2016), MEDLINE (1950 to February 2016), and www.clinicaltrials.gov without using any language limits.
Selection criteria
All randomized controlled trials (RCTs) comparing 'iron plus ESA' or 'iron alone' versus 'ESA alone' in people with CIA were eligible for inclusion.
Data collection and analysis
We used standard methodological procedures expected by Cochrane.
Main results
We included eight RCTs (12 comparisons) comparing ESA plus iron versus ESA alone enrolling 2087 participants. We did not find any trial comparing iron alone versus ESAs alone in people with CIA. None of the included RCTs reported overall survival. There was a beneficial effect of iron supplementation to ESAs compared with ESAs alone on hematopoietic response (risk ratio (RR) 1.17, 95% confidence interval (CI) 1.09 to 1.26; P < 0.0001; 1712 participants; 11 comparisons; high‐quality evidence). Assuming a baseline risk of 35% to 80% for hematopoietic response without iron supplementation, between seven and 16 patients should be treated to achieve hematopoietic response in one patient. In subgroup analyses, RCTs that used intravenous (IV) iron favored ESAs and iron (RR 1.20 (95% CI 1.10 to 1.31); P < 0.00001; 1321 participants; eight comparisons), whereas we found no evidence for a difference in hematopoietic response in RCTs using oral iron (RR 1.04 (95% CI 0.87 to 1.24); P = 0.68; 391 participants; three comparisons). There was no evidence for a difference between the subgroups of IV and oral iron (P = 0.16). There was no evidence for a difference between the subgroups of types of iron (P = 0.31) and types of ESAs (P = 0.16) for hematopoietic response.
The iron supplementation to ESAs might be beneficial as fewer participants treated with iron supplementation required red blood cell (RBC) transfusions compared to the number of participants treated with ESAs alone (RR 0.74 (95% CI 0.60 to 0.92); P = 0.007; 1719 participants; 11 comparisons; moderate‐quality evidence). Assuming a baseline risk of 7% to 40% for RBC transfusion without iron supplementation, between 10 and 57 patients should be treated to avoid RBC transfusion in one patient.
We found no evidence for a difference in the median time to hematopoietic response with addition of iron to ESAs (hazard ratio (HR) 0.93 (95% CI 0.67 to 1.28); P = 0.65; 1042 participants; seven comparisons; low‐quality evidence). In subgroup analyses, RCTs in which dextran (HR 0.95 (95% CI 0.36 to 2.52); P = 0.92; 340 participants; three comparisons), sucrose iron (HR 1.15 (95% CI 0.60 to 2.21); P = 0.67; 102 participants; one comparison) and sulfate iron (HR 1.24 (95% CI 0.99 to 1.56); P = 0.06; 55 participants; one comparison) were used showed no evidence for difference between iron supplementation versus ESAs alone compared with RCTs in which gluconate (HR 0.78 (95% CI 0.65 to 0.94); P = 0.01; 464 participants; two comparisons) was used for median time to hematopoietic response (P = 0.02). There was no evidence for a difference between the subgroups of route of iron administration (P = 0.13) and types of ESAs (P = 0.46) for median time to hematopoietic response.
Our results indicated that there could be improvement in the hemoglobin (Hb) levels with addition of iron to ESAs (mean difference (MD) 0.48 (95% CI 0.10 to 0.86); P = 0.01; 827 participants; seven comparisons; low‐quality evidence). In RCTs in which IV iron was used there was evidence for a difference (MD 0.84 (95% CI 0.21 to 1.46); P = 0.009; 436 participants; four comparisons) compared with oral iron (MD 0.07 (95% CI ‐0.19 to 0.34); P = 0.59; 391 participants; three comparisons) for mean change in Hb level (P = 0.03). RCTs in which dextran (MD 1.55 (95% CI 0.62 to 2.47); P = 0.001; 102 participants; two comparisons) was used showed evidence for a difference with iron supplementation versus ESAs alone compared with RCTs in which gluconate (MD 0.54 (95% CI ‐0.15 to 1.22); P = 0.12; 334 participants; two comparisons) and sulfate iron (MD 0.07 (95% CI ‐0.19 to 0.34); P = 0.59; 391 participants; three comparisons) were used for mean change in Hb level (P = 0.007). RCTs in which epoetin was used showed evidence for a difference with iron supplementation versus ESAs alone (MD 0.77 (95% CI 0.25 to 1.29); P = 0.004; 337 participants; five comparisons) compared with darbepoetin use (MD 0.10 (95% CI ‐0.13 to 0.33); P = 0.38; 490 participants; two comparisons) for mean change in Hb level (P = 0.02).
We found no evidence for a difference in quality of life with addition of iron to ESAs (standardized mean difference 0.01 (95% CI ‐0.10 to 0.12); P = 0.88; 1124 participants; three RCTs; high‐quality evidence).
We found no evidence for a difference in risk of grade III‐IV thromboembolic events (RR 0.95 (95% CI 0.54 to 1.65); P = 0.85; 783 participants; three RCTs; moderate‐quality evidence). The incidence of treatment‐related mortality (TRM) was 0% (997 participants; four comparisons; high‐quality evidence).
Other common adverse events included vomiting, asthenia, and leukopenia, and were similar in both arms.
Overall the risk of bias across outcomes was high to low. Since the included RCTs had shorter follow‐up duration (up to 20 weeks), the long‐term effects of iron supplementation are unknown. Our main reasons for downgrading the quality of evidence were inconsistency across the included studies and imprecision of results.
Authors' conclusions
Our systematic review shows that addition of iron to ESAs offers superior hematopoietic response, reduces the risk of RBC transfusions, and improves Hb levels, and appears to be well tolerated. None of the included RCTs reported overall survival. We found no evidence for a difference in quality of life with iron supplementation.
PICOs
Plain language summary
The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving erythropoiesis‐stimulating agents
Review question: Is iron alone or iron as a supplement to erythropoiesis‐stimulating agents (ESAs) superior to ESAs alone in the management of people diagnosed with chemotherapy‐induced anemia (CIA)?
Background: The current treatment of CIA is ESAs, which increase the production of red blood cells (erythropoiesis), and in some cases ESAs and iron. In some cases, strategies such as no therapy or wait and watch with clinical oversight and red blood cell transfusion may be safe and suitable options. We conducted a systematic review to evaluate the benefits and harms of iron in the management of CIA.
Search date: The evidence is current to February 2016.
Study characteristics: We included eight industry‐funded randomized controlled trials (RCTs) comparing ESAs plus iron versus ESAs alone enrolling 2087 participants. We did not find any trial comparing iron alone versus ESAs alone.
Study funding source: All the included trials were industry funded.
Key results: Adding iron to ESAs improves the hematopoietic response in people with CIA. Use of iron with ESAs might reduce the risk of blood transfusions and improve hemoglobin. We found no improvement in quality of life with addition of iron. We found no evidence for a difference in time to hematopoietic response and risk of development of blood clot in veins of people with CIA treated with iron and ESAs compared with ESAs alone. There were zero treatment‐related deaths among 997 participants in the four trials that reported this outcome. Other harms included constipation, vomiting, and diarrhea, and were similar with ESAs and iron compared with ESAs alone. None of the trials reported data on survival.
Quality of evidence: The quality of evidence for hematopoietic response was high. The quality of evidence for red blood cell transfusion was moderate, as the pooled estimate had large variation. The quality of evidence for change in hemoglobin and time to hematopoietic response was low, as the pooled estimates had large variation and results were not similar across studies. The quality of evidence for quality of life was high. The quality of evidence for risk of blood clots in veins was moderate due to variation in pooled estimate. Since the included RCTs had shorter follow‐up duration (up to 20 weeks), the long‐term effects of iron supplementation are unknown.
